Pathogenic antibodies to coagulation factors. Part II. Fibrinogen, prothrombin, thrombin, factor V, factor XI, factor XII, factor XIII, the protein C system and von Willebrand factor

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 7, 2005, Pages 1385-1391

  Lollar, P ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTITHROMBIN; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 ANTIBODY; FIBRINOGEN; HEPARIN COFACTOR II; HIRUDIN; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN; THROMBIN RECEPTOR; THROMBOMODULIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR ANTIBODY; BLOOD CLOTTING FACTOR;

ANTIGEN BINDING; BLOOD CLOTTING DISORDER; CROSS REACTION; ENZYME INHIBITION; HEMOSTASIS; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; VON WILLEBRAND DISEASE; ANIMAL; BIOSYNTHESIS; BLOOD CLOTTING; IMMUNE SYSTEM; IMMUNOLOGY; MACROMOLECULE; PATHOLOGY; THROMBOCYTE DISORDER;

ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD PLATELET DISORDERS; FACTOR V; FACTOR XI; FACTOR XII; FACTOR XIII; FIBRINOGEN; HUMANS; IMMUNE SYSTEM; MACROMOLECULAR SUBSTANCES; PROTEIN C; PROTHROMBIN; THROMBIN; VON WILLEBRAND FACTOR;

EID: 25144498054     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01228.x     Document Type: Review

References (65)

1. Lollar P. Pathogenic antibodies to coagulation factors. I. Factor VIII and factor IX. J Thromb Haemost 2004; 2: 1082-95.
2. Esmon CT. The protein C pathway. Chest 2003; 124: 26S-32S.
3. Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost 2003; 1: 1471-8.
4. Schoenecker JG, Johnson RK, Lesher AP, Day JD, Love SD, Hoffman MR, Ortel TL, Parker W, Lawson JH. Exposure of mice to topical bovine thrombin induces systemic autoimmunity. Am J Pathol 2001; 159: 1957-69.
5. Ortel TL, Charles LA, Keller FG, Marcom PK, Oldham HN Jr, Kane WH, Macik BG. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol 1994; 45: 128-35.
6. Zehnder JL, Leung LL. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood 1990; 76: 2011-6.
7. Schoenecker JG, Johnson RK, Fields RC, Lesher AP, Domzalski T, Baig K, Lawson JH, Parker W. Relative purity of thrombin-based hemostatic agents used in surgery. J Am Coll Surg 2003; 197: 580-90.
8. Ortel TL, Mercer MC, Thames EH, Moore KD, Lawson JH. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 2001; 233: 88-96.
9. Knobl P, Lechner K. Acquired factor V inhibitors. Baillieres Clin Haematol 1998; 11: 305-18.
10. Caers J, Reekmans A, Jochmans K, Naegels S, Mana F, Urbain D, Reynaert H. Factor V inhibitor after injection of human thrombin (tissucol) into a bleeding peptic ulcer. Endoscopy 2003; 35: 542-4.
11. Stubbs MT, Bode W. A player of many parts: the spotlight falls on thrombin's structure. Thromb Res 1993; 69: 1-58.
12. Lollar P, Esmon CT. Involvement of thrombin anion-binding exosites 1 and 2 in the activation of human factor VIII. J Biol Chem 1996; 271: 13882-7.
13. La Spada AR, Skalhegg BS, Henderson R, Schmer G, Pierce R, Chandler W. Brief report: fatal hemorrhage in a patient with an acquired inhibitor of human thrombin. N Engl J Med 1995; 333: 494-7.
14. Sie P, Bezeaud A, Dupouy D, Archipoff G, Freyssinet JM, Dugoujon JM, Serre G, Guillin MC, Boneu B. An acquired antithrombin autoantibody directed toward the catalytic center of the enzyme. J Clin Invest 1991; 88: 290-6.
15. Colwell NS, Tollefsen DM, Blinder MA. Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder. Br J Haematol 1997; 97: 219-26.
16. Lian F, Li H, Colwell NS, Lollar P, Tollefsen DM. A monoclonal antibody that binds to exosite II of thrombin accelerates inhibition by antithrombin and inhibits activation of factor VIII. Biochemistry 2001; 40: 8508-13.
17. Arnaud E, Lafay M, Gaussem P, Picard V, Jandrot-Perrus M, Aiach M, Rendu F. An autoantibody directed against human thrombin anion-binding exosite in a patient with arterial thrombosis: effects on platelets, endothelial cells, and protein C activation. Blood 1994; 84: 1843-50.
18. Lawson JH, Pennell BJ, Olson JD, Mann KG. Isolation and characterization of an acquired antithrombin antibody. Blood 1990; 76: 2249-57.
19. Ortel TL, Devore-Carter D, Quinn-Allen MA, Kane WH. Deletion analysis of recombinant human factor V. Evidence for a phosphatidylserine binding site in the second C-type domain. J Biol Chem 1992; 267: 4189-98.
20. Nesheim ME, Nichols WL, Cole TL, Houston JG, Schenk RB, Mann KG, Bowie EJ. Isolation and study of an acquired inhibitor of human coagulation factor V. J Clin Invest 1986; 77: 405-15.
21. Kalafatis M, Simioni P, Tormene D, Beck DO, Luni S, Girolami A. Isolation and characterization of an antifactor V antibody causing activated protein C resistance from a patient with severe thrombotic manifestations. Blood 2002; 99: 3985-92.
22. Ortel TL, Moore KD, Quinn-Allen MA, Okamura T, Sinclair AJ, Lazarchick J, Govindan R, Carmagnol F, Kane WH. Inhibitory anti-factor V antibodies bind to the factor V, C2 domain and are associated with hemorrhagic manifestations. Blood 1998; 91: 4188-96.
23. Macedo-Ribeiro S, Bode W, Huber R, Quinn-Allen MA, Kim SW, Ortel TL, Bourenkov GP, Bartunik HD, Stubbs MT, Kane WH, Fuentes-Prior P. Crystal structures of the membrane-binding C2 domain of human coagulation factor V. Nature 1999; 402: 434-9.
24. Izumi T, Kim SW, Greist A, Macedo-Ribeiro S, Fuentes-Prior P, Bode W, Kane WH, Ortel TL. Fine mapping of inhibitory anti-factor V antibodies using factor V, C2 domain mutants. Identification of two antigenic epitopes involved in phospholipid binding. Thromb Haemost 2001; 85: 1048-54.
25. Arnout J, Vermylen J. Current status and implications of autoimmune antiphospholipid antibodies in relation to thrombotic disease. J Thromb Haemost 2004; 1: 931-42.
26. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4.
27. Fleck RA, Rapaport SI, Rao LV. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988; 72: 512-9.
28. Galli M, Barbui T. Antiprothrombin antibodies: detection and clinical significance in the antiphospholipid syndrome. Blood 1999; 93: 2149-57.
29. Rao LV, Hoang AD, Rapaport SI. Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid. Blood 1996; 88: 4173-82.
30. Willems GM, Janssen MP, Pelsers MM, Comfurius P, Galli M, Zwaal RF, Bevers EM. Role of divalency in the high-affinity binding of anticardiolipin antibody-beta 2-glycoprotein I complexes to lipid membranes. Biochemistry 1996; 35: 13833-42.
31. Field SL, Chesterman CN, Dai YP, Hogg PJ. Lupus antibody bivalency is required to enhance prothrombin binding to phospholipid. J Immunol 2001; 166: 6118-25.
32. Simmelink MJ, Horbach DA, Derksen RH, Meijers JC, Bevers EM, Willems GM, de Groot PG. Complexes of anti-prothrombin antibodies and prothrombin cause lupus anticoagulant activity by competing with the binding of clotting factors for catalytic phospholipid surfaces. Br J Haematol 2001; 113: 621-9.
33. Galli M, Finazzi G, Bevers EM, Barbui T. Kaolin clotting time and dilute Russell's viper venom time distinguish between prothrombin-dependent and beta 2-glycoprotein I-dependent antiphospholipid antibodies. Blood 1995; 86: 617-23.
34. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RF. Lupus anticoagulant IgGs (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost 1991; 66: 629-32.
35. Loeliger A. Prothrombin as a co-factor of the circulating anticoagulant in systemic lupus erythematosus? Thromb Diath Haemorrh 1959; 3: 273-6.
36. Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemostasis Thrombosis 1972; 1: 75-95.
37. Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 1983; 61: 684-92.
38. Edson JR, Vogt JM, Hasegawa DK. Abnormal prothrombin crossed- immunoelectrophoresis in patients with lupus inhibitors. Blood 1984; 64: 807-16.
39. Horbach DA, van Oort E, Derksen RH, de Groot PG. The contribution of anti-prothrombin-antibodies to lupus anticoagulant activity-discrimination between functional and non-functional anti-prothrombin-antibodies. Thromb Haemost 1998; 79: 790-5.
40. Hwang KK, Grossman JM, Visvanathan S, Chukwuocha RU, Woods VL Jr, Le DT, Hahn BH, Chen PP. Identification of antithrombin antibodies in the antiphospholipid syndrome that interfere with the inactivation of thrombin by antithrombin. J Immunol 2001; 167: 7192-8.
41. Mitchell CA, Rowell JA, Hau L, Young JP, Salem HH. A fatal thrombotic disorder associated with an acquired inhibitor of protein C. N Engl J Med 1987; 317: 1638-42.
42. Hwang KK, Yang CD, Yan W, Grossman JM, Hahn BH, Chen PP. A thrombin-cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C. Arthritis Rheum 2003; 48: 1622-30.
43. Sorice M, Arcieri P, Griggi T, Circella A, Misasi R, Lenti L, Di Nucci GD, Mariani G. Inhibition of protein S by autoantibodies in patients with acquired protein S deficiency. Thromb Haemost 1996; 75: 555-9.
44. Nojima J, Kuratsune H, Suehisa E, Kawasaki T, Machii T, Kitani T, Iwatani Y, Kanakura Y. Acquired activated protein C resistance associated with anti-protein S antibody as a strong risk factor for DVT in non-SLE patients. Thromb Haemost 2002; 88: 716-22.
45. Hurtado V, Montes R, Gris JC, Bertolaccini ML, Alonso A, Martinez-Gonzalez MA, Khamashta MA, Fukudome K, Lane DA, Hermida J. Autoantibodies against EPCR are found in antiphospholipid syndrome and are a risk factor for fetal death. Blood 2004; 104: 1369-74.
46. Simone JV, Cornet JA, Abildgaard CF. Acquired von Willebrand's syndrome in systemic lupus erythematosus. Blood 1968; 31: 806-12.
47. Federici AB, Rand JH, Bucciarelli P, Budde U, van Genderen PJ, Mohri H, Meyer D, Rodeghiero F, Sadler JE and Subcommittee on von Willebrand Factor. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 2000; 84: 345-9.
48. Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand disease. Mayo Clinic Proc 2002; 77: 181-7.
49. Handin RI, Martin V, Moloney WC. Antibody-induced von Willebrand's disease: a newly defined inhibitor syndrome. Blood 1976; 48: 393-405.
50. Fricke WA, Brinkhous KM, Garris JB, Roberts HR. Comparison of inhibitory and binding characteristics of an antibody causing acquired von Willebrand syndrome: an assay for von Willebrand factor binding by antibody. Blood 1985; 66: 562-9.
51. Bovill EG, Ershler WB, Golden EA, Tindle BH, Edson JR. A human myeloma-produced monoclonal protein directed against the active subpopulation of von Willebrand factor. Am J Clin Pathol 1986; 85: 115-23.
52. Mohri H, Motomura S, Kanamori H, Matsuzaki M, Watanabe S, Maruta A, Kodama F, Okubo T. Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 1998; 91: 3623-9.
53. Gan TE, Sawers RJ, Koutts J. Pathogenesis of antibody-induced acquired von Willebrand syndrome. Am J Hematol 1980; 9: 363-71.
54. van Genderen PJ, Vink T, Michiels JJ, 't Veer MB, Sixma JJ, van Vliet HH. Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of von Willebrand factor to collagen. Blood 1994; 84: 3378-84.
55. Richard C, Cuadrado MA, Prieto M, Batlle J, Lopez Fernandez MF, Rodriguez Salazar ML, Bello C, Recio M, Santoro T, Gomez Casares MT. Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells. Am J Hematol 1990; 35: 114-7.
56. Scrobohaci ML, Daniel MT, Levy Y, Marolleau JP, Brouet JC. Expression of GpIb on plasma cells in a patient with monoclonal IgG and acquired von Willebrand disease. Br J Haematol 1993; 84: 471-5.
57. Tefferi A, Hanson CA, Kurtin PJ, Katzmann JA, Dalton RJ, Nichols WL. Acquired von Willebrand's disease due to aberrant expression of platelet glycoprotein Ib by marginal zone lymphoma cells. Br J Haematol 1997; 96: 850-3.
58. Bracey AW, Wu AH, Aceves J, Chow T, Carlile S, Hoots WK. Platelet dysfunction associated with Wilms tumor and hyaluronic acid. Am J Hematol 1987; 24: 247-57.
59. Luboshitz J, Lubetsky A, Schliamser L, Kotler A, Tamarin I, Inbal A. Pharmacokinetic studies with FVIII/von Willebrand factor concentrate can be a diagnostic tool to distinguish between subgroups of patients with acquired von Willebrand syndrome. Thromb Haemost 2001; 85: 806-9.
60. Nawarawong W, Wyshock E, Meloni FJ, Weitz J, Schmaier AH. The rate of fibrinopeptide B release modulates the rate of clot formation: a study with an acquired inhibitor to fibrinopeptide B release. Br J Haematol 1991; 79: 296-301.
61. Ruiz-Arguelles A. Spontaneous reversal of acquired autoimmune dysfibrinogenemia probably due to an antiidiotypic antibody directed to an interspecies cross-reactive idiotype expressed on antifibrinogen antibodies. J Clin Invest 1988; 82: 958-63.
62. Goodrick MJ, Prentice AG, Copplestone JA, Pamphilon DH, Boon RJ. Acquired factor XI inhibitor in chronic lymphocytic leukaemia. J Clin Pathol 1992; 45: 352-3.
63. Daly HM, Carson PJ, Smith JK. Intracerebral haemorrhage due to acquired factor XIII inhibitor-successful response to factor XIII concentrate. Blood Coagul Fibrinolysis 1991; 2: 507-14.
64. Krumdieck R, Shaw DR, Huang ST, Poon MC, Rustagi PK. Hemorrhagic disorder due to an isoniazid-associated acquired factor XIII inhibitor in a patient with Waldenstrom's macroglobulinemia. Am J Med 1991; 90: 639-45.
65. Schnall SF, Duffy TP, Clyne LP. Acquired factor XI inhibitors in congenitally deficient patients. Am J Hematol 1987; 26: 323-8.